Does Rallies show 13F holders for EVGN?

Yes. Rallies tracks hedge fund and 13F ownership data for EVGN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is EVGN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EVGN. It does not provide personalized investment advice.

EVGN (EVOGENE LTD.) Stock Analysis - Hedge Fund Holdings

EVOGENE LTD. (EVGN) is a publicly traded Healthcare sector company. As of May 20, 2026, EVGN trades at $0.72 with a market cap of $8.47M and a P/E ratio of 0.00. EVGN moved +0.00% today. Year to date, EVGN is -34.16%; over the trailing twelve months it is -44.48%. Its 52-week range spans $0.70 to $3.32. Analyst consensus is buy with an average price target of $2.25. Rallies surfaces EVGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EVGN stock?

Hedge funds tracked by Rallies that own EVGN include Renaissance Technologies, Citadel Advisors, and Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for EVOGENE LTD..

EVGN Key Metrics

Key financial metrics for EVGN
Metric	Value
Price	$0.72
Market Cap	$8.47M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.32
52-Week Low	$0.70
Volume	31.89K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding EVGN

Renaissance Technologies holds 44.70K shares of EVGN, changed -0.22% as of Jun 30, 2024.
Citadel Advisors holds 15.89K shares of EVGN, changed -32.98% as of Dec 31, 2024.
Two Sigma holds 11.16K shares of EVGN, changed -15.11% as of Dec 31, 2024.

Latest EVGN News

Evogene expands to four pharma partnerships, secures $3.4M warrant proceeds — May 20, 2026
Evogene Receives Nasdaq Minimum Bid Price Notice, Faces September Compliance Deadline — Apr 2, 2026
Casterra Confirms Economically Viable Castor Oil Production in 74-Hectare Brazil Trials — Mar 31, 2026
Evogene Cuts Expenses 37% to $13.8M but Sees Revenue Drop to $3.9M — Mar 14, 2026
Evogene Cuts Expenses to $13.8M, Secures $3.4M Warrant Proceeds — Mar 5, 2026

EVGN Analyst Consensus

1 analysts cover EVGN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.25.

Common questions about EVGN

Who owns EVGN stock?: Hedge funds tracked by Rallies that own EVGN include Renaissance Technologies, Citadel Advisors, and Two Sigma. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for EVOGENE LTD..
Does Rallies show 13F holders for EVGN?: Yes. Rallies tracks hedge fund and 13F ownership data for EVGN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EVGN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EVGN. It does not provide personalized investment advice.